The HER2-targeted ADC binds HER2, is internalized, and releases a cleavable deruxtecan (DXd) topoisomerase I inhibitor payload that induces DNA damage and apoptosis in HER2+ cells; Fc-mediated ADCC and a bystander effect can also contribute.